Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 9c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance